Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from <i>Candida albicans</i>—In Silico, In Vitro and In Vivo Approaches

The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen <i>Candida albicans</i> by using in silico, in vitro and in viv...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	André L. S. Santos, Lys A. Braga-Silva, Diego S. Gonçalves, Lívia S. Ramos, Simone S. C. Oliveira, Lucieri O. P. Souza, Vanessa S. Oliveira, Roberto D. Lins, Marcia R. Pinto, Julian E. Muñoz, Carlos P. Taborda, Marta H. Branquinha
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2021-05-01
Rangatū:	Journal of Fungi
Ngā marau:	<i>Candida albicans</i> drug repurposing HIV protease inhibitors secreted aspartic proteases lopinavir virulence
Urunga tuihono:	https://www.mdpi.com/2309-608X/7/6/424
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!